Assessment of dupilumab in children with moderate-to-severe type 2 asthma with or without evidence of allergic asthma.

导出原文传递

翻译打印收藏纠错

作者： Nikolaos G,Papadopoulos ^[1] ; Stanley J,Szefler ^[2] ; Leonard B,Bacharier ^[3] ; Jorge F,Maspero ^[4] ; Christian,Domingo ^[5] ; Alessandro,Fiocchi ^[6] ; Jason K,Lee ^[7] ; Nadia,Daizadeh ^[8] ; David J,Lederer ^[9] ; Megan,Hardin ^[8] ; Rebecca,Gall ^[9] ; Michel,Djandji ^[8] ; Shahid,Siddiqui ^[9] ; Juby A,Jacob-Nara ^[10] ; Yamo,Deniz ^[9] ; Paul J,Rowe ^[10]

作者单位： Allergy Department, The 2nd Pediatric Clinic, University of Athens, Athens, Greece. ^[1] Department of Pediatrics, The Breathing Institute, The University of Colorado School of Medicine and Children's Hospital Colorado, Aurora, Colorado, USA. ^[2] Division of Allergy, Immunology and Pulmonary Medicine, The Monroe Carell Jr. Children's Hospital at Vanderbilt University Medical Center, Nashville, Tennessee, USA. ^[3] Allergy and Respiratory Medicine, The Fundación CIDEA, Buenos Aires, Argentina. ^[4] Pulmonary Service, The Corporació Sanitària Parc Taulí, Sabadell, Autonomous University of Barcelona, Barcelona, Spain. ^[5] Department of Allergy, The Bambino Gesù Children's Hospital, IRCCS, Rome, Italy. ^[6] Division of Adult Clinical Immunology and Allergy, Internal Medicine, Evidence Based Medical Educator and Toronto Allergy and Asthma Clinic, Toronto, Ontario, Canada. ^[7] Sanofi, Cambridge, Massachusetts, USA. ^[8] Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA. ^[9] Sanofi, Bridgewater, New Jersey, USA. ^[10]

关键词 allergic asthma exacerbation percentage predicted FEV1, dupilumab